REMEDI study: Improving malaria diagnosis and treatment in Nigeria

Not Applicable

Completed

• Conditions: Diagnosis and appropriate treatment of malaria; Infections and Infestations; Unspecified malaria

• Registration Number: ISRCTN12605216
• Lead Sponsor: niversity of California, San Francisco (USA)

Brief Summary

1. 2015 results in https://www.ncbi.nlm.nih.gov/pubmed/25877471 (added 21/01/2019) 2. 2016 results in https://www.ncbi.nlm.nih.gov/pubmed/27315831 (added 21/01/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-10-18
• Study Completion: 2013-12-15
• Last Update Posted: 11 February 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

1. Adult aged over 17 years and having purchased malaria drugs for either him/herself or an accompanying minor at an enrolled study site
2. Customers must be willing to be assigned to any of the study intervention groups
3. Participating drugs shops must sell at least one type of antimalarial drug

Exclusion Criteria

1. Pregnant women who are seeking malaria treatment for herself are excluded because the recommended treatment for malaria is a different drug regimen than one than the study can provide
2. Any individual seeking treatment for illnesses other than malaria
3. Any adult who is purchasing malaria for a minor and the minor is not present at the time of enrollment
4. Because the study involves a follow-up survey conducted via phone, participants who cannot provide at least one phone number at which they can be reached are excluded
5. Drug shops that do not sell antimalarial drugs are excluded

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Malaria rapid diagnostic test result measured at baseline

Secondary Outcome Measures

Name	Time	Method
<br> Assessed 4 days after enrollment and testing and will include:<br> 1. Self-reported treatment with anti-malarial medication<br> 2. Self-reported treatment with non-antimalarial medications<br> 3. Perceptions of drug shop vendors ability to perform rapid diagnostic tests<br> 4. Perceptions of rapid diagnostic tests in general<br> 5. Cost effectiveness<br> 6. Perceptions of the text message reminders<br>